You cannot apply for this job anymore (deadline was 16 Sep 2017).
Browse the current job offers or choose an item in the top navigation above.
Your function within the department
The two PhD students will join the research group of Heinz Jacobs. The Jacobs group is part of the division of Tumor Biology & Immunology at the Netherlands Cancer Institute. The main research focus of the group is DNA Damage Tolerance (DDT), programmed mutagenesis and epigenetics during lymphocyte development.
Job description
Using established genetically engineered mouse models (GEMMs) and organoids/cell lines thereof, the PhD students will address the role of DDT in genome maintenance, tissue stem cell maintenance, and cancer suppression. The project covers a broad range of technologies. Both candidates are supposed to work closely together and with other lab members. Excellent core facilities with experienced scientific staff members warrant additional support.
To address the molecular and mutagenic consequences of DDT defects, we seek an experienced and ambitious molecular/medical biologist with strong affinity for bioinformatics. To address the systemic and cellular consequences, we seek an experienced and ambitious molecular/medical biologist with experience/ strong commitment in animal studies and organoid cultures.
Fixed-term contract: 4 years.
You will be employed for a period of 4 years. The gross salary per month is € 2.612,- to € 3.217,- according to the standard PhD scales and depends on previous experience. The terms of employment will be in accordance with the CAO Ziekenhuizen (Collective Labour Agreement for Hospitals). Furthermore you will have the opportunity to follow high-quality courses offered by the OOA oncology graduate school throughout your PhD.
Amsterdam is a very livable city with many cultural amenities. The institute is located within a 20 minute tram or bicycle ride from the center of Amsterdam and within 20 minutes from Schiphol airport by car, bus or bicycle.
The Netherlands Cancer Institute, for more than 100 years at the international forefront of cancer research and treatment.
We like to make it easy for you, sign in for these and other useful features: